Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by inthnoon Sep 28, 2021 1:07pm
181 Views
Post# 33931126

onc

onc

"RE:RE:RE:RE:Acceleron in advanced talks for $11 Bln sale - relationship


The putative reasoning for the interest in the acquisition of Acceleron involves the company's early stageTGF-β antagonist."

Hey notable, I do not give a rats you know what about some other company in advanced talks. Their product is an early stage idea as you have quoted and they are in advanced talks for billions....onc has been around 20 + plus years and what are we, still and early stage company. So much for the nasdaq listing helping us out at all, no institutional support at all. I want them to succed as much as anybody but sitting on their keesters at home making a million + dollars is not doing it for me. If our product is so good , get on a plane and go sit in their office and make a pitch.Yeah, just me ranting and I admit it and they really need to have something to show for it when the next quarterly comes out, but  I am sure they will find some way to put it off, heck if the analysts are even asking well then there sure has to be a reason for it. Okay, now done with my rant now go ONC go.

<< Previous
Bullboard Posts
Next >>